Versartis Closes Series C Financing
Versartis, an emerging biotechnology company has completed a $25 million Series C financing lead by new investor Aisling Capital. Also participating in the round were existing investors Index Ventures, New Leaf Venture Partners and Advent Venture Partners' Advent Life Sciences fund.
16 January 2013•3 mins read
